Daily Stock Analysis, EIGR, Eiger BioPharmaceuticals Inc, priceseries

Eiger BioPharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
10.98
Close
11.40
High
11.55
Low
10.98
Previous Close
11.07
Daily Price Gain
0.33
YTD High
15.33
YTD High Date
Apr 3, 2019
YTD Low
9.80
YTD Low Date
Jan 2, 2019
YTD Price Change
1.09
YTD Gain
10.57%
52 Week High
18.00
52 Week High Date
May 18, 2018
52 Week Low
8.20
52 Week Low Date
May 3, 2018
52 Week Price Change
2.00
52 Week Gain
21.28%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
6.70
Jul 10. 2017
7.42
14 Trading Days
10.77%
Link
LONG
Aug 28. 2017
8.20
Sep 21. 2017
10.58
17 Trading Days
29.00%
Link
LONG
Sep 29. 2017
11.00
Oct 16. 2017
12.62
11 Trading Days
14.73%
Link
LONG
Dec 19. 2017
12.40
Jan 5. 2018
13.11
11 Trading Days
5.74%
Link
LONG
May 14. 2018
10.75
May 24. 2018
12.26
8 Trading Days
14.07%
Link
LONG
Aug 14. 2018
10.05
Sep 5. 2018
12.22
15 Trading Days
21.61%
Link
LONG
Dec 31. 2018
10.16
Feb 8. 2019
13.97
27 Trading Days
37.51%
Link
Company Information
Stock Symbol
EIGR
Exchange
NasdaqGM
Company URL
http://www.eigerbio.com
Company Phone
650-279-9845
CEO
David A. Cory
Headquarters
California
Business Address
350 CAMBRIDGE AVE, SUITE 350, PALO ALTO, CA 94306
Sector
-
Industry Category
-
Industry Group
-
CIK
0001305253
About

Eiger BioPharmaceuticals, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of biopharmaceutical products. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Description

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. It portfolio of products include Sarasar, an indication for the hepatitis delta virus infection; Exendin, which is used for the treatment of hypoglycemia associated with bariatric surgery; and Bestatin that is used for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.